AU2014332346B2 - Novel peptide compositions - Google Patents

Novel peptide compositions Download PDF

Info

Publication number
AU2014332346B2
AU2014332346B2 AU2014332346A AU2014332346A AU2014332346B2 AU 2014332346 B2 AU2014332346 B2 AU 2014332346B2 AU 2014332346 A AU2014332346 A AU 2014332346A AU 2014332346 A AU2014332346 A AU 2014332346A AU 2014332346 B2 AU2014332346 B2 AU 2014332346B2
Authority
AU
Australia
Prior art keywords
weight
peptide
amino acid
peptides
xaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014332346A
Other languages
English (en)
Other versions
AU2014332346A1 (en
Inventor
Richard Franklin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tarix Pharmaceuticals Ltd
Original Assignee
Tarix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarix Pharmaceuticals Ltd filed Critical Tarix Pharmaceuticals Ltd
Publication of AU2014332346A1 publication Critical patent/AU2014332346A1/en
Application granted granted Critical
Publication of AU2014332346B2 publication Critical patent/AU2014332346B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2014332346A 2013-10-11 2014-10-01 Novel peptide compositions Ceased AU2014332346B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361890056P 2013-10-11 2013-10-11
US61/890,056 2013-10-11
US201461940095P 2014-02-14 2014-02-14
US61/940,095 2014-02-14
PCT/US2014/058646 WO2015054006A2 (en) 2013-10-11 2014-10-01 Novel peptide compositions

Publications (2)

Publication Number Publication Date
AU2014332346A1 AU2014332346A1 (en) 2016-05-05
AU2014332346B2 true AU2014332346B2 (en) 2019-01-24

Family

ID=52813728

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014332346A Ceased AU2014332346B2 (en) 2013-10-11 2014-10-01 Novel peptide compositions

Country Status (14)

Country Link
US (2) US9133241B2 (enExample)
EP (1) EP3054967A4 (enExample)
JP (1) JP2017501967A (enExample)
KR (1) KR20160065969A (enExample)
CN (1) CN105828831A (enExample)
AU (1) AU2014332346B2 (enExample)
BR (1) BR112016007816A2 (enExample)
CA (1) CA2926641A1 (enExample)
CL (1) CL2016000836A1 (enExample)
IL (1) IL244956B (enExample)
MX (1) MX2016004660A (enExample)
RU (1) RU2016112931A (enExample)
SG (1) SG11201602661PA (enExample)
WO (1) WO2015054006A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017150327A1 (ja) * 2016-03-03 2017-09-08 不二製油グループ本社株式会社 神経栄養因子の脳内分泌促進するための食品添加用組成物
JP6983247B2 (ja) * 2017-02-16 2021-12-17 ケアジェン カンパニー, リミテッドCaregen Co., Ltd. サリチル酸とペプチドとの結合体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011595A2 (en) * 2005-07-15 2007-01-25 Neuren Pharmaceuticals Limited Neural regeneration peptides and antioxidants protect neurons from degeneration

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
US20020168761A1 (en) 2000-01-24 2002-11-14 Gour Barbara J. Peptidomimetic modulators of cell adhesion
WO1998002452A2 (en) 1996-07-12 1998-01-22 Mcgill University Compounds and methods for modulating cell adhesion
US7563862B2 (en) 2001-08-24 2009-07-21 Neuren Pharmaceuticals Limited Neural regeneration peptides and methods for their use in treatment of brain damage
WO2003018754A2 (en) 2001-08-24 2003-03-06 Neuronz Limited Neural regeneration peptide and methods for their use in treatment of brain damage
AU2003293807A1 (en) * 2002-12-24 2004-07-22 Algonomics N.V. Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
WO2005042561A2 (en) 2003-10-31 2005-05-12 Neuren Pharmaceuticals Limited Neural regeneration peptides and methods of use
AU2011274474B2 (en) * 2010-07-09 2015-06-18 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
US20130210726A1 (en) * 2012-02-10 2013-08-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of peripheral vascular disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011595A2 (en) * 2005-07-15 2007-01-25 Neuren Pharmaceuticals Limited Neural regeneration peptides and antioxidants protect neurons from degeneration

Also Published As

Publication number Publication date
CA2926641A1 (en) 2015-04-16
BR112016007816A2 (pt) 2017-12-05
WO2015054006A2 (en) 2015-04-16
RU2016112931A3 (enExample) 2018-06-20
IL244956B (en) 2019-10-31
RU2016112931A (ru) 2017-11-16
US20170275333A1 (en) 2017-09-28
WO2015054006A3 (en) 2015-06-04
EP3054967A2 (en) 2016-08-17
JP2017501967A (ja) 2017-01-19
US9133241B2 (en) 2015-09-15
SG11201602661PA (en) 2016-05-30
AU2014332346A1 (en) 2016-05-05
MX2016004660A (es) 2016-11-14
IL244956A0 (en) 2016-05-31
CL2016000836A1 (es) 2016-09-16
EP3054967A4 (en) 2017-04-19
US20150105335A1 (en) 2015-04-16
KR20160065969A (ko) 2016-06-09
CN105828831A (zh) 2016-08-03

Similar Documents

Publication Publication Date Title
AU2018205186B2 (en) Angiotensin in treating brain conditions
US10960045B2 (en) Methods and compositions for the treatment of epidermolysis bullosa
US20180050079A1 (en) Angiotensin peptides in treating marfan syndrome and related disorders
US20160074464A1 (en) Angiotensins in muscular dystrophy
CA2940751C (en) Uses of an angiotensin (1-7) peptide for the delayed treatment of stroke
US9133241B2 (en) Peptide compositions
US20160296591A1 (en) Compositions and methods for treatment of bdnf-related conditions
WO2015057403A2 (en) Compositions and methods for treatment of inflammatory bowel disease
WO2025122594A1 (en) Improved methods and compositions for the treatment of pemphigus or pemphigoid disease
WO2016010844A1 (en) Methods and compositions for the treatment of stroke

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired